ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
Celularity Inc. Warrant
0.0500
0.0000
成交量:
3.44万
成交额:
1,397.78
市值:
- -
市盈率:
- -
高:
0.0500
开:
0.0400
低:
0.0400
收:
0.0500
数据加载中...
总览
公司
新闻
公告
公司资料
公司名字:
Celularity Inc. Warrant
交易所:
NASDAQ
成立时间:
- -
员工人数:
- -
公司地址:
- -
官网:
http://www.celularity.com
邮编:
- -
电话:
- -
传真:
- -
简介:
Celularity Inc.根据特拉华州法律于2016年8月29日成立。Cellarity是一家临床阶段的生物技术公司,通过开发现成的胎盘源性异基因T细胞,利用嵌合抗原受体细胞、自然杀伤细胞(“NK”)细胞和间充质样粘附基质细胞(“ASCs”)进行工程化,针对癌症,传染病和退行性疾病,引领细胞医学的下一个发展方向。Cellarity相信,通过利用胎盘独特的生物学特性和现成的可用性,它将能够开发出治疗解决方案,以满足全球对有效、易获得和负担得起的治疗方法的重大需求。
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/CELUW/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CELUW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CELUW\",,,,,undefined,":{"symbol":"CELUW","market":"US","secType":"STK","nameCN":"Celularity Inc. Warrant","latestPrice":0.05,"timestamp":1752696000000,"preClose":0.05,"halted":0,"volume":34358,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"盘后交易","change":0,"latestTime":"07-16 19:46:21 EDT","open":0.04001,"high":0.05,"low":0.04,"amount":1397.7778,"amplitude":0.2,"askPrice":0.2525,"askSize":10000,"bidPrice":0.0302,"bidSize":100,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752710400000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.05,"volumeRatio":1.599326},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CELUW\",,,,,undefined,":{"symbol":"CELUW","floatShares":0,"roa":"-17.42%","roe":"-232.51%","lyrEps":0,"volumeRatio":1.599326,"shares":0,"dividePrice":0,"high":0.05,"amplitude":0.2,"preClose":0.05,"low":0.04,"week52Low":0.0075,"pbRate":"0.00","psRate":"0.00","week52High":0.7511,"institutionHeld":0,"latestPrice":0.05,"committee":-0.980198,"eps":0,"divideRate":0,"volume":34358,"delay":0,"ttmEps":0,"open":0.04001,"prevYearClose":0.018,"prevWeekClose":0.0556,"prevMonthClose":0.0443,"prevQuarterClose":0.0443,"fiveDayClose":0.05,"twentyDayClose":0.0556,"sixtyDayClose":0.04},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.celularity.com","stockEarnings":[{"period":"1week","weight":0.3889},{"period":"1month","weight":-0.004},{"period":"3month","weight":0.2531},{"period":"6month","weight":0.845},{"period":"1year","weight":1.7933},{"period":"ytd","weight":1.7778}],"compareEarnings":[{"period":"1week","weight":0.0029},{"period":"1month","weight":0.0421},{"period":"3month","weight":0.1835},{"period":"6month","weight":0.0516},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.0615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Celularity Inc.根据特拉华州法律于2016年8月29日成立。Cellarity是一家临床阶段的生物技术公司,通过开发现成的胎盘源性异基因T细胞,利用嵌合抗原受体细胞、自然杀伤细胞(“NK”)细胞和间充质样粘附基质细胞(“ASCs”)进行工程化,针对癌症,传染病和退行性疾病,引领细胞医学的下一个发展方向。Cellarity相信,通过利用胎盘独特的生物学特性和现成的可用性,它将能够开发出治疗解决方案,以满足全球对有效、易获得和负担得起的治疗方法的重大需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.360826},{"month":2,"riseRate":0.666667,"avgChangeRate":0.096569},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.027554},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.00408},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.006779},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.004047},{"month":7,"riseRate":0.666667,"avgChangeRate":0.056529},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.05734},{"month":9,"riseRate":0,"avgChangeRate":-0.186078},{"month":10,"riseRate":0.666667,"avgChangeRate":0.174956},{"month":11,"riseRate":0.5,"avgChangeRate":-0.122596},{"month":12,"riseRate":0.5,"avgChangeRate":0.87154}],"exchange":"NASDAQ","name":"Celularity Inc. Warrant","nameEN":"Celularity Inc. Warrant"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"CELUW\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CELUW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CELUW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CELUW\",market:\"US\",delay:false,,,undefined,":{}}}